$26.88+0.08 (+0.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Viking Therapeutics (VKTX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+45.9%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼227.1%
−359.6
FY21→FY25CAGR —
Diluted EPS▼215.8%
−3.19
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+45.9%
77.2mn → 112.7mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 586,166.0 | 344,955.0 | 101,644.0 | 63,806.0 | 54,234.0 | 44,981.0 | ▲239.4% | +66.4% |
Selling, general & admin | 62,406.0 | 48,387.0 | 49,277.0 | 37,021.0 | 16,121.0 | 10,701.0 | ▼1.8% | +45.8% |
Total operating expenses | 648,572.0 | 393,398.0 | 151,015.0 | 100,915.0 | 70,414.0 | 55,700.0 | ▲160.5% | +63.0% |
Operating incomefeeds ROC rank | −648,572.0 | −393,342.0 | −150,921.0 | −100,827.0 | −70,355.0 | −55,682.0 | ▼160.6% | — |
Other income, net | 21,377.0 | 33,759.0 | 41,052.0 | 15,020.0 | 1,547.0 | 710.0 | — | — |
Pretax income | −627,195.0 | −359,583.0 | −109,869.0 | −85,807.0 | −68,808.0 | −54,972.0 | ▼227.3% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −627,195.0 | −359,639.0 | −109,963.0 | −85,895.0 | −68,867.0 | −54,990.0 | ▼227.1% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −5.41 | −3.19 | −1.01 | −0.91 | −0.90 | −0.71 | ▼215.8% | — |
Diluted shares (mn) | 118.05 | 112.67 | 109.04 | 94.35 | 76.83 | 77.20 | ▲3.3% | +9.9% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-11 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

